Targeting matrix metalloproteinases in acute inflammatory shock syndromes

Combinatorial Chemistry and High Throughput Screening

Volumn 15, Issue 7, 2012, Pages 555-570

  Qiu, Zheng ^a   Hu, Jialiang ^a   Van Den Steen, Philippe E ^b   Opdenakker, Ghislain ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Inflammation; Lipopolysaccharide; Matrix metalloproteinase; MMP inhibitor; Neutrophil; Sepsis

Indexed keywords

BATIMASTAT; BB 1101; BB 2293; CD14 ANTIGEN; CHEMOKINE; COLLAGENASE 3; CYTOKINE; DOXYCYCLINE; GELATINASE A; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; IW 449; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 28; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; NEUTROPHIL COLLAGENASE; RO 319790; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; SURFACTANT PROTEIN D; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE INFLAMMATORY SHOCK SYNDROME; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; COMBINATORIAL CHEMISTRY; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENDOTOXEMIA; ENZYME INHIBITION; GENE INACTIVATION; HEPATITIS; HUMAN; INFLAMMATORY DISEASE; LIVER NECROSIS; MEMBRANE DAMAGE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SEPTIC SHOCK; SHOCK; VENTILATOR INDUCED LUNG INJURY; X RAY CRYSTALLOGRAPHY;

ACUTE DISEASE; ANIMALS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; SHOCK, SEPTIC; STRUCTURE-ACTIVITY RELATIONSHIP; SYNDROME;

EID: 84865352027     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/138620712801619159     Document Type: Article

References (138)

1. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2(3), 161-174. (Pubitemid 37328786)
2. Sorokin, L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol., 2010, 10(10), 712-723.
3. Opdenakker, G.; Van den Steen, P.E.; Dubois, B.; Nelissen, I.; Van Coillie, E.; Masure, S.; Proost, P.; Van Damme, J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol., 2001, 69(6), 851-859. (Pubitemid 32577883)
4. Van Lint, P.; Libert, C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol., 2007, 82(6), 1375-1381. (Pubitemid 350276947)
5. Cauwe, B.; Van den Steen, P.E.; Opdenakker, G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol., 2007, 42(3), 113-185. (Pubitemid 46911962)
6. Cauwe, B.; Opdenakker, G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol., 2010, 45(5), 351-423.
7. Yong, V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci., 2005, 6(12), 931-944. (Pubitemid 41753087)
8. Parks, W.C.; Wilson, C.L.; López-Boado, Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol., 2004, 4(8), 617-629. (Pubitemid 39025047)
9. Krüger, A.; Kates, R.E.; Edwards, D.R. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim. Biophys. Acta., 2010, 1803(1), 95-102.
10. Hu, J.; Van den Steen, P.E.; Sang, Q.X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov., 2007, 6(6), 480-498. (Pubitemid 47064570)
11. Hadler-Olsen, E.; Fadnes, B.; Sylte, I.; Uhlin-Hansen, L.; Winberg, J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J., 2011, 278(1), 28-45.
12. Dejonckheere, E.; Vandenbroucke, R.E.; Libert, C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov. Today, 2011, 16(17-18), 762-778.
13. Van den Steen, P.E.; Dubois, B.; Nelissen, I.; Rudd, P.M.; Dwek, R.A.; Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol., 2002, 37(6), 375-536. (Pubitemid 36071972)
14. Paemen, L.; Martens, E.; Masure, S.; Opdenakker, G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur. J. Biochem., 1995, 234, 759-765. (Pubitemid 26024332)
15. Masure, S.; Billiau, A.; Van Damme, J.; Opdenakker, G. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim. Biophys. Acta, 1990, 1054: 317-325. (Pubitemid 20281095)
16. Knight, C.G.; Willenbrock, F.; Murphy, G. A novel coumarinlabelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett., 1992, 296, 263-266.
17. Hu, J.; Fiten, P.; Van den Steen, P.E.; Chaltin, P.; Opdenakker, G. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Anal. Chem., 2005, 77, 2116-2124. (Pubitemid 40463828)
18. St-Pierre, Y.; Desrosiers, M.; Tremblay, P.; Esteve, P.O.; Opdenakker, G. Flow cytometric analysis of gelatinase B (MMP-9) activity using immobilized fluorescent substrate on microspheres. Cytometry, 1996, 25, 374-380. (Pubitemid 26418493)
19. Hu, J.; Van den Steen, P.E.; Houde, M.; Ilenchuk, T.T.; Opdenakker, G. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem. Pharmacol., 2004, 67, 1001-1009. (Pubitemid 38201645)
20. Russell, J.A.; Boyd, J.; Nakada, T.; Thair, S.; Walley, K.R. Molecular mechanisms of sepsis. Contrib. Microbiol., 2011, 17, 48-85.
21. van der Poll, T.; van Zoelen, M.A.; Wiersinga, W.J. Regulation of pro-and anti-inflammatory host responses. Contrib. Microbiol., 2011, 17, 125-136.
22. Chong, D.L.; Sriskandan, S. Pro-inflammatory mechanisms in sepsis. Contrib. Microbiol., 2011, 17, 86-107.
23. Shubin, N.J.; Monaghan, S.F.; Ayala, A. Anti-inflammatory mechanisms of sepsis. Contrib. Microbiol., 2011, 17, 108-124.
24. Opdenakker, G.; Van den Steen, P.E.; Laureys, G.; Hunninck, K.; Arnold, B. Neutralizing antibodies in gene-defective hosts. Trends Immunol., 2003, 24, 94-100. (Pubitemid 36120646)
25. Overall CM, Dean RA. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev., 2006, 25(1), 69-75 (Pubitemid 43723983)
26. López-Otín, C.; Matrisian, L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer, 2007, 7(10), 800-808. (Pubitemid 47463671)
27. Fligiel, S.E.; Standiford, T.; Fligiel, H.M.; Tashkin, D.; Strieter, R.M.; Warner, R.L.; Johnson, K.J.; Varani, J. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum. Pathol., 2006, 37(4), 422-430.
28. Tressel, S.L.; Kaneider, N.C.; Kasuda, S.; Foley, C.; Koukos, G.; Austin, K.; Agarwal, A.; Covic, L.; Opal, S.M.; Kuliopulos, A. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med., 2011, 3(7), 370-384.
29. Wohlschlaeger, J.; Stubbe, H.D.; Schmitz, K.J.; Kawaguchi, N.; Takeda, A.; Takeda, N.; Hinder, F.; Baba, H.A. Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model. Pathol. Res. Pract., 2005, 201(12), 809-817. (Pubitemid 43071568)
30. Cena, J.; Lalu, M.M.; Rosenfelt, C.; Schulz R. Endothelial dependence of matrix metalloproteinase-mediated vascular hyporeactivity caused by lipopolysaccharide. Eur. J. Pharmacol., 2008, 582(1-3), 116-122.
31. Steinberg, J.; Halter, J.; Schiller, H.; Gatto, L.; Carney, D.; Lee, H.M.; Golub, L.; Nieman, G. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock, 2005, 24(4), 348-356. (Pubitemid 41416521)
32. Gurney, K.J.; Estrada, E.Y.; Rosenberg, G.A. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol. Dis., 2006, 23(1), 87-96. (Pubitemid 43903633)
33. Tester, A.M.; Cox, J.H.; Connor, A.R.; Starr, A.E.; Dean, R.A.; Puente, X.S.; López-Otín, C.; Overall, C.M. LPS Responsiveness and Neutrophil Chemotaxis In Vivo Require PMN MMP-8 Activity. PLoS ONE, 2007, 2(3), e312-322.
34. Quintero, P.A.; Knolle, M.D.; Cala, L.F.; Zhuang, Y.; Owen, C.A. Matrix Metalloproteinase-8 Inactivates Macrophage Inflammatory Protein-1α to Reduce Acute Lung Inflammation and Injury in Mice. J. Immunol., 2010, 184(3), 1575-1588.
35. Lin, M.; Jackson, P.; Tester, A.M.; Diaconu, E.; Overall, C.M.; Blalock, J.E.; Pearlman, E. Matrix Metalloproteinase-8 Facilitates Neutrophil Migration through the Corneal Stromal Matrix by Collagen Degradation and Production of the Chemotactic Peptide Pro-Gly-Pro. Am. J. Pathol., 2008, 173(1), 144-153. (Pubitemid 351947962)
36. Phillipson, M.; Kubes, P. The neutrophil in vascular inflammation. Nat. Med., 2011, 17(11), 1381-1390.
37. Masure, S.; Proost, P.; Van Damme, J.; Opdenakker, G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem., 1991, 198(2), 391-398.
38. Renckens, R.; Roelofs, J.J.; Florquin, S.; de Vos, A.F.; Lijnen, H.R.; van't Veer, C.; van der Poll, T. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J. Immunol., 2006, 176(6), 3735-3741. (Pubitemid 43364020)
39. Albaiceta, G.M.; Gutiérrez-Fernández, A.; Parra, D.; Astudillo, A.; García-Prieto, E.; Taboada, F.; Fueyo, A. Lack of matrix metalloproteinase-9 worsens ventilator-induced lung injury. Am. J. Physiol. Lung Cell Mol. Physiol., 2008, 294(3), L535-543. (Pubitemid 351468853)
40. Malik, M.; Bakshi, C.S.; McCabe, K.; Catlett, S.V.; Shah, A.; Singh, R.; Jackson, P.L.; Gaggar, A.; Metzger, D.W.; Melendez, J.A.; Blalock, J.E.; Sellati, T.J. Matrix Metalloproteinase 9 Activity Enhances Host Susceptibility to Pulmonary Infection with Type A and B Strains of Francisella tularensis. J. Immunol., 2007, 178, 1013-1020. (Pubitemid 46095174)
41. Wielockx, B.; Lannoy, K.; Shapiro, S.D.; Itoh, T.; Itohara, S.; Vandekerckhove, J.; Libert, C. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat. Med., 2001, 7(11), 1202-1208. (Pubitemid 33063775)
42. Senft, A.P.; Korfhagen, T.R.; Whitsett, J.A.; Shapiro, S.D.; LeVine, A.M. Surfactant protein-D regulates soluble CD14 through matrix metalloproteinase- 12. J. Immunol., 2005, 174(8), 4953- 4959. (Pubitemid 40514461)
43. Kolaczkowska, E.; Koziol, A.; Plytycz, B.; Arnold, B.; Opdenakker, G. Altered apoptosis of inflammatory neutrophils in MMP-9-deficient mice is due to lower expression and activity of caspase-3. Immunology Letters, 2009, 126(1-2), 73-82.
44. Lorente, L.; Martín, M.M.; Labarta, L.; Díaz, C.; Solé-Violán, J.; Blanquer, J.; Orbe, J.; Rodríguez, J.A.; Jiménez, A.; Borreguero- León, J.M.; Belmonte, F.; Medina, J.C.; Llimiñana, M.C.; Ferrer- Agüero, J.M.; Ferreres, J.; Mora, M.L.; Lubillo, S.; Sánchez, M.; Barrios, Y.; Sierra, A.; Páramo, J.A. Matrix metalloproteinase-9, - 10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit. Care., 2009, 13(5), R158-164.
45. Hoffmann, U.; Brueckmann, M.; Borggrefe, M. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis? Crit. Care., 2009, 13(6), 1006-1015.
46. Crocker, S.J.; Frausto, R.F.; Whitton, J.L.; Milner, R. A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia. Glia., 2008, 56(11), 1187-1198.
47. Sen, A.I.; Shiomi, T.; Okada, Y.; D'Armiento, J.M. Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury. Exp. Lung Res., 2010, 36(10), 615-624.
48. Stach, K.; Kälsch, A.I.; Nguyen, X.D.; Elmas, E.; Kralev, S.; Lang, S.; Weiss, C.; Borggrefe, M.; Kälsch, T. 1α,25-dihydroxyvitamin D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial cells. Cardiology, 2011, 118(2), 107-115.
49. Reel, B.; Sala-Newby, G.B.; Huang, W.C.; Newby, A.C. Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br. J. Pharmacol., 2011, 163(8), 1679-1690.
50. Yin, C.S.; Lee, H.J.; Hong, S.J.; Chung, J.H.; Koh, H.G. Microarray analysis of gene expression in chondrosarcoma cells treated with bee venom. Toxicon, 2005, 45(1), 81-91. (Pubitemid 39586571)
51. Rikimaru, A.; Komori, K.; Sakamoto, T.; Ichise, H.; Yoshida, N.; Yana, I.; Seiki, M. Establishment of an MT4-MMP-deficient mouse strain representing an efficient tracking system for MT4- MMP/MMP-17 expression in vivo using β-galactosidase. Genes to Cells, 2007, 12, 1091-1100. (Pubitemid 47365679)
52. Locati, M.; Deuschle, U.; Massardi, M.L.; Martinez, F.O.; Sironi, M.; Sozzani, S.; Bartfai, T.; Mantovani, A. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol., 2002, 168(7), 3557-3362.
53. Klawitter, M.; Quero, L.; Bertolo, A.; Mehr, M.; Stoyanov, J.; Nerlich, A.G.; Klasen, J.; Aebli, N.; Boos, N.; Wuertz, K. Human MMP28 expression is unresponsive to inflammatory stimuli and does not correlate to the grade of intervertebral disc degeneration. J. Negat. Results Biomed., 2011, 10, 9-15.
54. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev., 1999, 99, 2735-2776.
55. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 2002, 295, 2387-2392. (Pubitemid 34270240)
56. Babine, R.E.; Bender, S.L. Molecular Recognition of Protein- Ligand Complexes: Applications to Drug Design. Chem. Rev., 1997, 97, 1359-1472. (Pubitemid 127659602)
57. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science, 1999, 284, 1667-1670. (Pubitemid 29291376)
58. Castelhano, A.L.; Billedeau, R.; Dewdney, N.; Donnelly, S.; Horne, S.; Kurz, L.J.; Liak, T.J.; Martin, R.; Uppington, R.; Yuan, Z.; Krantz, A. Novel indolactam-based inhibitors of matrix metalloproteinases. Bioorg. Med. Chem. Lett., 2006, 5, 1415-1420.
59. Mun-Bryce, S.; Rosenberg, G.A. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am. J. Physiol., 1998, 274(5Pt2), R1203-1211.
60. Rosenberg, G.A.; Estrada, E.Y.; Mobashery, S. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: Differences in response based on strains and solvents. Brain Res. 2007, 1133(1), 186-192. (Pubitemid 46123248)
61. Solorzano, C.C.; Ksontini, R.; Pruitt, J.H.; Auffenberg, T.; Tannahill, C.; Galardy, R.E.; Schultz, G.P.; MacKay, S.L.; Copeland, E.M.; Moldawer, L.L. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock, 1997, 7(6), 427-431. (Pubitemid 127726465)
62. Tsuji, F.; Oki, K.; Okahara, A.; Suhara, H.; Yamanouchi, T.; Sasano, M.; Mita, S.; Horiuchi, M. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis. Cytokine, 2002, 17(6), 294-300.
63. Lalu, M.M.; Gao, C.Q.; Schulz, R. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol. Cell Biochem., 2003, 251(1-2), 61-66. (Pubitemid 37220710)
64. Brown, S.; Li, Z.H.; Kotra, L.P.; Tanaka, Y.; Fridman, R.; Mobashery, S.; Bernardo, M.M. Potent and Selective Mechanism-Based Inhibition of Gelatinases. J. Am. Chem. Soc., 2000, 122, 6799-6800. (Pubitemid 30490016)
65. Kleifeld, O.; Kotra, L.P.; Gervasi, D.C.; Brown, S.; Bernardo, M.M.; Fridman, R.; Mobashery, S.; Sagi, I. X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme. J. Biol. Chem., 2001, 276, 17125-17131.
66. Ikejiri, M.; Bernardo, M.M.; Meroueh, S.O.; Brown, S.; Chang, M.; Fridman, R.; Mobashery, S. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J. Org. Chem., 2005, 70, 5709-5712. (Pubitemid 40980782)
67. Ferry, G., Boutin, J.A., Atassi, G., Fauchere, J.L., Tucker, G.C. Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. Mol. Divers., 1997, 2, 135-146. (Pubitemid 127824135)
68. Koivunen, E.; Arap, W.; Valtanen, H.; Rainisalo, A.; Medina, O.P.; Heikkilä, P.; Kantor, C.; Gahmberg, C.G.; Salo, T.; Konttinen, Y.T.; Sorsa, T.; Ruoslahti, E.; Pasqualini, R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol., 1999, 17, 768-774. (Pubitemid 29365104)
69. Björklund, M.; Valtanen, H.; Savilahti, H.; Koivunen, E. Use of intein-directed peptide biosynthesis to improve serum stability and bioactivity of a gelatinase inhibitory peptide. Comb. Chem. High Throughput Screen., 2003, 6, 29-35. (Pubitemid 36206830)
70. Hu, J.; Van den Steen, P.E.; Dillen, C.; Opdenakker, G. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol., 2005, 70, 535-544. (Pubitemid 40978543)
71. Hu, J.; Dubois, V.; Chaltin, P.; Fiten, P.; Dillen, C.; Van den Steen, P.E.; Opdenakker, G. Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb. Chem. High Throughput Screen, 2006, 9, 599-611. (Pubitemid 44320409)
72. Qiu, Z.; Yan, M.; Li, Q.; Liu, D.; Van den Steen, P.E.; Wang, M.; Opdenakker, G.; Hu, J. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17). J. Enzyme Inhib. Med. Chem., 2011, in press.
73. Acharya, M.R.; Venitz, J.; Figg, W.D.; Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat., 2004, 7, 195-208. (Pubitemid 39024520)
74. Paemen, L.; Martens, E.; Norga, K.; Masure, S.; Roets, E.; Hoogmartens, J.; Opdenakker, G. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol., 1996, 52, 105-111. (Pubitemid 26199112)
75. Brundula, V.; Rewcastle, N.B.; Metz, L.M.; Bernard, C.C.; Yong, V.W. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain, 2002, 125, 1297-1308. (Pubitemid 34587139)
76. Ramamurthy, N.S.; Rifkin, B.R.; Greenwald, R.A.; Xu, J.W.; Liu, Y.; Turner, G.; Golub, L.M.; Vernillo, A.T. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines. J. Periodontol., 2002, 73, 726-734.
77. Lukkonen, A.; Sorsa, T.; Salo, T.; Tervahartiala, T.; Koivunen, E.; Golub, L.; Simon, S.; Stenman, U.H. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int. J. Cancer, 2000, 86, 577-581. (Pubitemid 30249741)
78. Yrjanheikki, J., Tikka, T., Keinanen, R., Goldsteins, G., Chan, P.H., Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA, 1999, 96, 13496-13500.
79. Yong, V.W., Power, C., Forsyth, P., Edwards, D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci., 2001, 2, 502-511. (Pubitemid 33676585)
80. Shapira, L.; Soskolne, W.A.; Houri, Y.; Barak, V.; Halabi, A.; Stabholz, A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect. Immun., 1996, 64(3), 825-828. (Pubitemid 26065554)
81. Milano, S.; Arcoleo, F.; D'Agostino, P.; Cillari, E. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob. Agents Chemother., 1997, 41(1), 117-121. (Pubitemid 26428144)
82. Steinberg, J.; Halter, J.; Schiller, H.; Gatto, L.; Carney, D.; Lee, H.M.; Golub, L.; Nieman, G. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock, 2005, 24(4), 348-356. (Pubitemid 41416521)
83. Steinberg, J.; Halter, J.; Schiller, H.J.; Dasilva, M.; Landas, S.; Gatto, L.A.; Maisi, P.; Sorsa, T.; Rajamaki, M.; Lee, H.M.; Nieman, G.F. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J. Surg. Res., 2003, 111(2), 185-195. (Pubitemid 36808908)
84. Halter, J.M.; Pavone, L.A.; Steinberg, J.M.; Gatto, L.A.; DiRocco, J.; Landas, S.; Nieman, G.F. Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture. Shock, 2006, 26(6), 587-591. (Pubitemid 44789633)
85. Maitra, S.R.; Bhaduri, S.; Valane, P.D.; Tervahartiala, T.; Sorsa, T.; Ramamurthy, N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock, 2003, 20(3), 280-285.
86. Kim, J.H.; Lee, S.Y.; Bak, S.M.; Suh, I.B.; Lee, S.Y.; Shin, C.; Shim, J.J.; In, K.H.; Kang, K.H.; Yoo, S.H. Effects of matrix metalloproteinase inhibitor on LPS-induced goblet cell metaplasia. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287(1), L127-133. (Pubitemid 38787659)
87. Asahi, M.; Asahi, K.; Jung, J.C.; del Zoppo, G.J.; Fini, M.E.; Lo, E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab., 2000, 20(12), 1681-1689.
88. Pfefferkorn, T.; Rosenberg, G.A. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke, 2003, 34(8), 2025-2030. (Pubitemid 36944801)
89. Murphy, G.; Docherty, A.J.P. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell Mol. Biol., 1992, 7, 120-125.
90. Murphy, G.; Willenbrock, F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol., 1995, 248, 496-510.
91. Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgeirsson, U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 1997, 74, 111-122. (Pubitemid 27455388)
92. Olson, M.W.; Gervasi, D.C.; Mobashery, S.; Fridman, R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J. Biol. Chem., 1997, 272, 29975-29983.
93. Sato, H.; Seiki, M. Membrane-type matrix metalloproteinases (MTMMPs) in tumor metastasis. J. Biochem. (Tokyo), 1996, 119, 209-215. (Pubitemid 26063238)
94. Lee, M.H.; Rapti, M.; Murphy, G. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. J. Biol. Chem., 2005, 280, 15967-15975. (Pubitemid 40616720)
95. Chirco, R.; Liu, X.W.; Jung, K.K.; Kim, H.R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev., 2006, 25, 99-113. (Pubitemid 43723986)
96. Zhou, N.; Paemen, L.; Opdenakker, G.; Froyen, G. Cloning and expression in Escherichia coli of a human gelatinase B-inhibitory single-chain immunoglobulin variable fragment (scFv). FEBS Lett., 1997, 414(3), 562-566. (Pubitemid 27390668)
97. Shimanovich, I.; Mihai, S.; Oostingh, G.J.; Ilenchuk, T.T.; Bröcker, E.B.; Opdenakker, G.; Zillikens, D.; Sitaru, C. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol., 2004, 204, 519-527. (Pubitemid 39585950)
98. Ramos-DeSimone, N.; Moll, U.M.; Quigley, J.P.; French, D.L. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma, 1993, 12, 349-363. (Pubitemid 24200110)
99. Wiel, E.; Pu, Q.; Leclerc, J.; Corseaux, D.; Bordet, R.; Lund, N.; Jude, B.; Vallet, B. Effects of the angiotensin-converting enzyme inhibitor perindopril on endothelial injury and hemostasis in rabbit endotoxic shock. Intensive Care Med., 2004, 30(8), 1652-1659. (Pubitemid 39094969)
100. Giebler, R.; Schmidt, U.; Koch, S.; Peters, J.; Scherer, R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit. Care Med., 1999, 27(3), 597-604. (Pubitemid 29162683)
101. Scherer, R.U.; Giebler, R.M.; Schmidt, U.; Paar, D.; Kox, W.J. The influence of C1-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Semin. Thromb. Hemost., 1996, 22(4), 357-366. (Pubitemid 26414415)
102. Ruetten, H.; Thiemermann, C. Effect of calpain inhibitor I, an inhibitor of the proteolysis of I kappa B, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br. J. Pharmacol., 1997, 121(4), 695-704. (Pubitemid 27260772)
103. Deaciuc, I.V.; D'Souza, N.B.; de Villiers, W.J.; Burikhanov, R.; Sarphie, T.G.; Hill, D.B.; McClain, C.J. Inhibition of caspases in vivo protects the rat liver against alcohol-induced sensitization to bacterial lipopolysaccharide. Alcohol. Clin. Exp. Res., 2001, 25(6), 935-943. (Pubitemid 32552502)
104. Grobmyer, S.R.; Armstrong, R.C.; Nicholson, S.C.; Gabay, C.; Arend, W.P.; Potter, S.H.; Melchior, M.; Fritz, L.C.; Nathan, C.F. Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock. Mol. Med., 1999, 5(9), 585-594. (Pubitemid 32936949)
105. Reis, J.; Tan, X.; Yang, R.; Rockwell, C.E.; Papasian, C.J.; Vogel, S.N.; Morrison, D.C.; Qureshi, A.A.; Qureshi, N. A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model. Innate Immun., 2008, 14(5), 319-329.
106. Sugiyama, T.; Fujita, M.; Koide, N.; Mori, I.; Yoshida, T.; Mori, H.; Yokochi, T. 2-aminopurine inhibits lipopolysaccharide-induced nitric oxide production by preventing IFN-beta production. Microbiol. Immunol., 2004, 48(12), 957-963. (Pubitemid 40040703)
107. Jourdain, M.; Carrette, O.; Tournoys, A.; Fourrier, F.; Mizon, C.; Mangalaboyi, J.; Goudemand, J.; Mizon, J.; Chopin, C. Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am. J. Respir. Crit. Care Med., 1997, 156(6), 1825-1833. (Pubitemid 28011789)
108. Yamazaki, M.; Asakura, H.; Aoshima, K.; Saito, M.; Jokaji, H.; Uotani, C.; Kumabashiri, I.; Morishita, E.; Ikeda, T.; Matsuda, T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb. Haemost., 1994, 72(3), 392-396.
109. Gómez, C.; Páramo, J.A.; Rocha, E. Effect of heparin and/or antithrombin III in a model of disseminated intravascular coagulation induced by endotoxin in rabbits. Sangre (Barc), 1992, 37(1), 5-10.
110. Wu, C.C.; Chen, S.J.; Szabó, C.; Thiemermann, C.; Vane, J.R. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br. J. Pharmacol., 1995, 114(8), 1666-1672.
111. Fletcher, D.S.; Agarwal, L.; Chapman, K.T.; Chin, J.; Egger, L.A.; Limjuco, G.; Luell, S.; MacIntyre, D.E.; Peterson, E.P.; Thornberry, N.A. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. J. Interferon Cytokine Res., 1995, 15(3), 243-248.
112. Siebeck, M.; Hoffmann, H.; Weipert, J.; Fritz, H. Effect of the elastase inhibitor eglin C in porcine endotoxin shock. Circ. Shock, 1992, 36(3), 174-179.
113. Pham, D.; Jeng, A.Y.; Escher, E.; Sirois, P.; Battistini, B. Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase /endothelin-converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats. J. Cardiovasc. Pharmacol., 2000, 36(5 Suppl 1), S362-366.
114. Ishii, K.; Ito, Y.; Katagiri, H.; Matsumoto, Y.; Kakita, A.; Majima, M. Neutrophil elastase inhibitor attenuates lipopolysaccharideinduced hepatic microvascular dysfunction in mice. Shock, 2002, 18(2), 163-168.
115. Hagiwara, S.; Iwasaka, H.; Hidaka, S.; Hasegawa, A.; Noguchi, T. 2009. Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm. Res., 2009, 58(4), 198-203.
116. Hagiwara, S.; Iwasaka, H.; Togo, K.; Noguchi, T. A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1. Inflammation, 2008, 31(4), 227-234.
117. Jourdain, M.; Tournoys, A.; Leroy, X.; Mangalaboyi, J.; Fourrier, F.; Goudemand, J.; Gosselin, B.; Vallet, B.; Chopin, C. Effects of N sup omega-nitro-L-arginine methyl ester on the endotoxininduced disseminated intravascular coagulation in porcine septic shock. Crit. Care Med., 1997, 25(3), 452-459. (Pubitemid 27152740)
118. Korbut, R.; Warner, T.D.; Gryglewski, R.J.; Vane, J.R. The effect of nitric oxide synthase inhibition on the plasma fibrinolytic system in septic shock in rats. Br. J. Pharmacol., 1994, 112(1), 289-291. (Pubitemid 24151741)
119. Robertson, F.M.; Offner, P.J.; Ciceri, D.P.; Becker, W.K.; Pruitt, B.A. Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch. Surg., 1994, 129(2), 149-155.
120. Tilahun, A.Y.; Theuer, J.E.; Patel, R.; David, C.S.; Rajagopalan, G. Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation. Mol. Ther., 2010, 18(6), 1143-1154.
121. Yuksel, M.; Okajima, K.; Uchiba, M.; Okabe, H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharideinduced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J. Pharmacol. Exp. Ther., 2003, 305(1), 298-305. (Pubitemid 36373864)
122. Tumurkhuu, G.; Koide, N.; Hiwasa, T.; Ookoshi, M.; Dagvadorj, J.; Abu Shadat Mohammod Norman; Iftakhar-E-Khuda, I.; Naiki, Y.; Komatsu, T.; Yoshida, T.; Yokochi, T. ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun., 2011, 17(1), 97-105.
123. Hoffmann, H.; Siebeck, M.; Spannagl, M.; Weis, M.; Geiger, R.; Jochum, M.; Fritz, H. Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. Am. Rev. Respir. Dis., 1990, 142(4), 782-788. (Pubitemid 20344644)
124. Ueki, M.; Taie, S.; Chujo, K.; Asaga, T.; Iwanaga, Y.; Ono, J.; Maekawa, N. Urinary trypsin inhibitor reduces inflammatory response in kidney induced by lipopolysaccharide. J. Biosci. Bioeng., 2007, 104(4), 315-320. (Pubitemid 350102407)
125. Inoue, K.; Takano, H.; Yanagisawa, R.; Sakurai, M.; Shimada, A.; Yoshino, S.; Sato, H.; Yoshikawa, T. Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Exp. Biol. Med. (Maywood)., 2005, 230(4), 281-287. (Pubitemid 40478253)
126. Wakahara, K.; Kobayashi, H.; Yagyu, T.; Matsuzaki, H.; Kondo, T.; Kurita, N.; Sekino, H.; Inagaki, K.; Suzuki, M.; Kanayama, N.; Terao, T. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor- alpha and interleukin-1 beta in macrophages. J. Infect. Dis., 2005, 191(6), 930-938. (Pubitemid 40349809)
127. Matsuzaki, H.; Kobayashi, H.; Yagyu, T.; Wakahara, K.; Kondo, T.; Kurita, N.; Sekino, H.; Inagaki, K.; Suzuki, M.; Kanayama, N.; Terao, T. Bikunin inhibits lipopolysaccharide-induced tumor necrosis factor alpha induction in macrophages. Clin. Diagn. Lab. Immunol., 2004, 11(6), 1140-1147. (Pubitemid 39540857)
128. Noman, A.S.; Koide, N.; Hassan, F.; I-E-Khuda, I.; Dagvadorj, J.; Tumurkhuu, G.; Islam, S.; Naiki, Y.; Yoshida, T.; Yokochi, T. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun., 2009, 15(1), 33-41.
129. Noman, A.S.; Koide, N.; Khuda, II.; Dagvadorj, J.; Tumurkhuu, G.; Naiki, Y.; Komatsu, T.; Yoshida, T.; Yokochi, T. Thalidomide inhibits lipopolysaccharide-induced nitric oxide production and prevents lipopolysaccharide-mediated lethality in mice. FEMS Immunol. Med. Microbiol., 2009, 56(3), 204-211.
130. Zhou, R.; Zheng, S.X.; Tang, W.; He, P.L.; Li, X.Y.; Yang, Y.F.; Li, Y.C.; Geng, J.G.; Zuo, J.P. Inhibition of inducible nitric-oxide synthase expression by (5R)-5-hydroxytriptolide in interferon gamma- and bacterial lipopolysaccharide-stimulated macrophages. J. Pharmacol. Exp. Ther., 2006, 316(1), 121-128. (Pubitemid 41832588)
131. Pu, Q.; Wiel, E.; Corseaux, D.; Bordet, R.; Azrin, M.; Ezekowitz, M.; Lund, N.; Jude, B.; Vallet, B. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit. Care Med., 2001, 29(16), 1181-1188. (Pubitemid 32554332)
132. Jung, W.K.; Choi, I.; Lee, D.Y.; Yea, S.S.; Choi, Y.H.; Kim, M.M.; Park, S.G.; Seo, S.K.; Lee, S.W.; Lee, C.M.; Park, Y.M.; Choi, I.W. Caffeic acid phenethyl ester protects mice from lethal endotoxin shock and inhibits lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW 264.7 macrophages via the p38/ERK and NF-kappaB pathways. Int. J. Biochem. Cell Biol., 2008, 40(11), 2572-2582.
133. Jiang, W.L.; Chen, X.G.; Qu, G.W.; Yue, X.D.; Zhu, H.B.; Tian, J.W.; Fu, F.H. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock, 2009, 32(6), 608-613.
134. Matsumoto, Y.; Ito, Y.; Hayashi, I.; Majima, M.; Ishii, K.; Katagiri, H.; Kakita, A. Effect of FR167653, a novel inhibitor of tumor necrosis factor-alpha and interleukin-1beta synthesis on lipopolysaccharide-induced hepatic microvascular dysfunction in mice. Shock, 2002, 17(5), 411-415.
135. Weitzberg, E.; Hemsén, A.; Rudehill, A.; Modin, A.; Wanecek, M.; Lundberg, J.M. Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br. J. Pharmacol., 1996, 118(3), 617-626. (Pubitemid 26180975)
136. Yamazaki, M.; Aoshima, K.; Mizutani, T.; Ontachi, Y.; Saito, M.; Morishita, E.; Asakura, H.; Matsuda, T.; Triplett, D.A. Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression. Blood Coagul. Fibrinolysis, 1999, 10(6), 321-330. (Pubitemid 29416076)
137. Sato, K.; Yoo, Y.C.; Fukushima, A.; Saiki, I.; Takahashi, T.A.; Fujihara, M.; Tono-Oka, S.; Azuma, I. A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia. Infect. Immun., 1995, 63(8), 2859-2866.
138. Dankesreiter, S.; Hoess, A.; Schneider-Mergener, J.; Wagner, H.; Miethke, T. Synthetic endotoxin-binding peptides block endotoxintriggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J. Immunol., 2000, 164(9), 4804-4811. (Pubitemid 30238083)